Udhayvir Grewal: Impressive data for PDAC outcomes by metastatic site
Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport Academy Medical Centre, shared a post on X by Erman Akkus, Medical Oncology Fellow at Ankara University, adding:
“Impressive data for PDAC outcomes by metastatic site.
Lung mets – immunogenic TIME – better biology – better outcomes.
Perfect use of metastasis-directed therapy if oligometastatic and lung only mets.
Now we have prospective data for PFS benefit in all comers population with oligometastatic PDAC-EXTEND trial.”
Quoting Erman Akkus’s post about a paper by Emily Alouani et al. published in ESMO GI Oncology:
“Metastatic site and survival in pancreatic cancer.
mOS and mPFS
- lung-only > peritoneum-only >liver-only >multi-site
- lung-only accounts 4.7% of syn met pancreatic cancers
More agressive local therapies in this subset?”
Authors: Emily Alouani et al.
More posts featuring Udhayvir Grewal and Erman Akkus.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023